

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GLUGAGON-LIKE	:	CIVIL ACTION
PEPTIDE-1 RECEPTOR AGONISTS	:	
(GLP-1 RAS) PRODUCTS	:	
LIABILITY LITIGATION	:	
<hr/>	:	
	:	
THIS DOCUMENT RELATES TO:	:	MDL No. 3094
	:	24-md-3094
<i>Ulrich v. Novo Nordisk A/S et al.</i>	:	
Case No. 2:24-cv-01554	:	
	:	HON. KAREN SPENCER MARSTON
<i>Shirley v. Novo Nordisk A/S et al.</i>	:	
Case No. 2:23-cv-04980	:	
<hr/>		

ORDER

AND NOW, this 26th day of July, 2024, in light of the telephonic conference on July 26, 2024, it is **ORDERED** that *Ulrich v. Novo Nordisk A/S et al.* (Case No. 2:24-cv-01554) and *Shirley v. Novo Nordisk A/S et al.* (Case No. 2:23-cv-04980) are **STAYED** pending a decision by the Judicial Panel on Multidistrict Litigation (“the Panel” or “JPML”) to transfer them to this MDL.¹

IT IS SO ORDERED.

/s/ Karen Spencer Marston
KAREN SPENCER MARSTON, J.

¹ Both actions allege the plaintiffs suffered venous thromboembolisms. In the Panel’s original Transfer Order, the Panel described the injuries common to the plaintiffs as being “gastrointestinal.” *See* Doc. No. 1 at 2. The parties must seek approval from the Panel prior to expanding to the scope of injuries included in this MDL.